Early autologous stem cell transplantation in poor-risk chronic lymphocytic leukaemia. Long-term results from the GCLLSG CLL3 trial focusing on incidence and type of secondary malignancies

被引：0

作者：

McClanahan, F. ^{[1
]}

Stilgenbauer, S. ^{[2
]}

Greinix, H. ^{[3
]}

Hensel, M. ^{[4
]}

Hertenstein, B. ^{[5
]}

Duehrsen, U. ^{[6
]}

Hentrich, M. ^{[7
]}

Truemper, L. ^{[8
]}

Sonnen, R.

Emmerich, B. ^{[9
]}

Knauf, W. ^{[10
]}

Hopfinger, G. ^{[3
]}

Hallek, M. ^{[11
]}

Kneba, M. ^{[12
]}

Schmitz, N.

Doehner, H. ^{[2
]}

Dreger, P. ^{[1
]}

机构：

[1] Univ Heidelberg Hosp, Heidelberg, Germany

[2] Univ Hosp Ulm, Ulm, Germany

[3] Univ Hosp Vienna, Vienna, Austria

[4] Mannheimer Onkolol Praxis, Mannheim, Germany

[5] Klinikum Bremen Mitte, Bremen, Germany

[6] Univ Hosp Essen, Essen, Germany

[7] Stadt Klinikum Munchen, Munich, Germany

[8] Univ Hosp Gottingen, Gottingen, Germany

[9] Tumorzentrum Munchen, Munich, Germany

[10] Onkol Gemeinschaftspraxis, Frankfurt, Germany

[11] Univ Hosp Cologne, Cologne, Germany

[12] Univ Hosp Kiel, Kiel, Germany

来源：

BONE MARROW TRANSPLANTATION | 2010年 / 45卷

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：S41 / S42

页数：2

共 41 条

[1] Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q-in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial
Dreger, Peter
Doehner, Hartmut
Greinix, Hildegard
McClanahan, Fabienne
Hensel, Manfred
Hertenstein, Bernd
Duehrsen, Ulrich
Hentrich, Markus
Truemper, Lorenz
Sonnen, Ruth
Ernmerich, Bertold
Knauf, Wolfgang Ulrich
Hopfinger, Georg
Hallek, Michael
Kneba, Michael
Schmitz, Norbert
Stilgenbauer, Stephan
[J]. BLOOD, 2009, 114 (22) : 362 - 362
[2] Early autologous stem cell transplantation (SCT) in genetically poor-risk chronic lymphocytic leukemia is feasible and effective: Results from a prospective multicenter study (GCLLSG CLL3 protocol).
Dreger, P
Busch, R
Stilgenbauer, S
Greinix, H
Hensel, M
Hertenstein, B
Duehrsen, U
Hentrich, M
Truemper, LH
Schmitz, N
Ritgen, M
Emmerich, B
Hallek, MJ
Kneba, M
Dohner, H
[J]. BLOOD, 2004, 104 (11) : 45A - 45A
[3] Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial
Scheffold, Annika
Jebaraj, Billy Michael Chelliah
Jaramillo, Sonia
Tausch, Eugen
Steinbrecher, Daniela
Hahn, Michael
Boettcher, Sebastian
Ritgen, Matthias
Bunjes, Donald
Zeis, Matthias
Stadler, Michael
Uharek, Lutz
Scheid, Christoph
Hegenbart, Ute
Hallek, Michael
Kneba, Michael
Schmitz, Norbert
Doehner, Hartmut
Dreger, Peter
Stilgenbauer, Stephan
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (02) : 342 - 346
[4] Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial
Dreger, Peter
Doehner, Hartmut
McClanahan, Fabienne
Busch, Raymonde
Ritgen, Matthias
Greinix, Hildegard
Fink, Anna-Maria
Knauf, Wolfgang
Stadler, Michael
Pfreundschuh, Michael
Duehrsen, Ulrich
Brittinger, Guenter
Hensel, Manfred
Schetelig, Johannes
Winkler, Dirk
Buehler, Andreas
Kneba, Michael
Schmitz, Norbert
Hallek, Michael
Stilgenbauer, Stephan
[J]. BLOOD, 2012, 119 (21) : 4851 - 4859
[5] Efficacy and prognostic implications of early autologous stem cell transplantation for poor-risk chronic lymphocytic leukemia (CLL).
Dreger, P
von Neuhoff, N
Sonnen, R
Kuse, R
Seyfarth, B
Lorenz, G
Glass, B
Schmitz, N
[J]. BLOOD, 2000, 96 (11) : 483A - 483A
[6] A prospective multicenter trial on nonmyeloablative allogeneic stem cell transplantation (NST) for poor-risk chronic lymphocytic leukemia (CLL):: Final results of the GCLLSG CLL3X study
Dreger, P.
Stilgenbauer, S.
Boettcher, S.
Ritgen, M.
Busch, R.
Bunjes, D.
Beelen, D.
Cohen, S.
Hegenbart, U.
Schubert, J.
Hertenstein, B.
Stadler, M.
Glass, B.
Burchert, A.
Uharek, L.
Basara, N.
Humpe, A.
Duehrsen, U.
Hallek, M.
Schmitz, N.
Kneba, M.
Doehner, H.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
[7] High CD34+ cell yields and low rate of secondary MDS/AML using intensive mobilisation for early autologous stem cell transplantation in genetically poor-risk CLL:: results from a prospective multicentre study (GCLLSG CLL3 protocol)
Dreger, P
Stilgenbauer, S
Busch, R
Greinix, H
Hensel, M
Hertenstein, B
Duehrsen, U
Hentrich, M
Glass, B
Ritgen, M
Emmerich, B
Hallek, M
Kneba, M
Schmitz, N
Döhner, H
[J]. BONE MARROW TRANSPLANTATION, 2005, 35 : S67 - S67
[8] Early autologous stem cell transplantation for poor-risk Chronic Lymphocytic Leukemia (CLL): prognostic factors for feasibility and molecular outcome
Dreger, P
von Neuhoff, N
Wittkowsky, G
Sonnen, R
Seyfarth, B
Kuse, R
Glass, B
Schmitz, N
[J]. BONE MARROW TRANSPLANTATION, 2001, 27 : S36 - S37
[9] Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial
Scheffold, Annika
Jebaraj, Billy Michael Chelliah
Tausch, Eugen
Boettcher, Sebastian
Ritgen, Matthias
Bunjes, Donald
Zeis, Matthias
Stadler, Michael
Uharek, Lutz
Scheid, Christof
Hegenbart, Ute
Hallek, Michael
Kneba, Michael
Schmitz, Norbert
Doehner, Hartmut
Dreger, Peter
Stilgenbauer, Stephan
[J]. BLOOD, 2014, 124 (21)
[10] Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)
Dreger, Peter
Stilgenbauer, Stephan
Boettcher, Sebastian
Ritgen, Matthias
Dietrich, Sascha
Bunjes, Donald
Beelen, Dietrich Wilhelm
Cohen, Sandra
Hegenbart, Ute
Schubert, Joerg
Stadler, Michael
Glass, Bertram
Burchert, Andreas
Uharek, Lutz
Hallek, Michael
Kneba, Michael
Schmitz, Norbert
Doehner, Hartmut
[J]. BLOOD, 2008, 112 (11) : 212 - 212

← 1 2 3 4 5 →